# The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer

> **NCT03154983** · PHASE2 · UNKNOWN · sponsor: **Zhou Fuxiang** · enrollment: 48 (estimated)

## Conditions studied

- Metastatic Gastric Cancer

## Interventions

- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT03154983
- **Lead sponsor:** Zhou Fuxiang
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-05-20
- **Primary completion:** 2020-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2020-12-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03154983

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03154983, "The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03154983. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*